ADMET<i>In</i><i>Vitro</i>Profiling – Utility and Applications in Lead Discovery

Kerns, Edward H.; Zhang, Xun; Di, Li

doi:10.1002/0471266949.bmc118.pub2

Cited by 1 publication

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the objectives of this research was to investigate the hypothesis that the new scaffold (4-aroyl- N -benzylarylacetamides) might engage other kinases than Src. Therefore, a variety of solid tumor and hematopoetic cancer cell lines was selected for screening regardless of their dependance on Src kinase, including stomach cancer (N87) and myelogenous leukemia (MV4-11, K562 and HL60) ( 22 ). Our results are presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…There is a universal agreement that the physicochemical and pharmacokinetic properties play an important role in the viability of compounds as leads that can be optimized into drug candidates. Early in vitro screening of compounds in high throughput assays that predict in vivo ADME properties has become the norm for drug discovery, both in the industrial and academic setting ( 22 ). Properties such as aqueous solubility and protein binding impact not only in vivo studies but also biochemical and in vitro cellular assays as well.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases

et al. 2022

View full text Add to dashboard Cite

Tirbanibulin (KX2-391, KX-01), a dual non-ATP (substrate site) Src kinase and tubulin-polymerization inhibitor, demonstrated a universal anti-cancer activity for variety of cancer types. The notion that KX2-391 is a highly selective Src kinase inhibitor have been challenged by recent reports on the activities of this drug against FLT3-ITD mutations in some leukemic cell lines. Therefore, we hypothesized that analogues of KX2-391 may inhibit oncogenic kinases other than Src. A set of 4-aroylaminophenyl-N-benzylacetamides were synthesized and found to be more active against leukemia cell lines compared to solid tumor cell lines. N-(4-(2-(benzylamino)-2-oxoethyl)phenyl)-4-chlorobenzamide (4e) exhibited activities at IC50 0.96 µM, 1.62 µM, 1.90 µM and 4.23 µM against NB4, HL60, MV4-11 and K562 leukemia cell lines, respectively. We found that underlying mechanisms of 4e did not include tubulin polymerization or Src inhibition. Such results interestingly suggested that scaffold-hopping of KX2-391 may change the two main underlying cytotoxic mechanisms (Src and tubulin). Kinase profiling using two methods revealed that 4e significantly reduces the activities of some other potent oncogenic kinases like the MAPK member ERK1/2 (>99%) and it also greatly upregulates the pro-apoptotic c-Jun kinase (84%). This research also underscores the importance of thorough investigation of total kinase activities as part of the structure-activity relationship studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%